OncLive Peer Exchange®

A panel of experts discuss recent updates including new data from ASH 2023 on the treatment of follicular lymphoma and mantle cell lymphoma as well as their clinical implications.

Experts discuss several recent data updates in polycythemia vera and myelofibrosis in the context of the treatment landscape and its impact on clinical practice.

A panel of expert oncologists explore advancements in the treatment of CLL, reviewing recent data updates from ASH 2023 and their potential impact on clinical practice.

A panel of expert oncologists explore recent advancements in the treatment of desmoid tumors, highlighting the approval of nirogacestat as the first FDA-approved in this treatment setting, and discussing its impact on clinical practice.

Expert panelists review recent advances in biomarker testing and the treatment landscape of uncommon EGFR mutations in non–small cell lung cancer.

A panel of experts on advanced non–small cell lung cancer discuss the overall treatment landscape and look at recent data in the context of clinical guidelines.

A panel of experts in gynecologic oncology explore advancements in the treatment of endometrial and cervical cancers, including breaking clinical trial data from ESMO 2023, and their potential impact on clinical practice.

A panel of experts discusses updates in metastatic melanoma biomarker testing and treatment presented at ESMO Congress 2023 and other recent meetings and reviews the data in the context of existing guidelines, the current treatment landscape, and its impact on clinical practice.

Expert panelists review recent updates in the treatment of advanced RCC following recent updates from the ESMO 2023 annual meeting and consider how they would approach specific scenarios in clinic.

A panel of medical oncologists, nurse practitioners, and nurses specializing in breast, lung, and gastric cancers have a comprehensive discussion on antibody-drug conjugates, molecular testing, and best practices for treating patients.

Expert panelists highlight some of the most critical unmet needs in multiple myeloma and consider how to provide optimal care for patients globally.

A panel of expert oncologists have a detailed discussion on emerging biomarkers, molecular testing strategies, and the evolving targeted treatment landscape in non–small cell lung cancer.

Thomas Herzog, MD, Thomas Krivak, MD, and Ian Hagemann, MD, PhD discuss the biological mechanisms behind homologous recombination deficiency (HRD) in ovarian cancer and expand on best practices for somatic and germline HRD testing and results-based patient management in the clinic.

An expert panel of gynecologic oncologists reviews recent data from the 2023 ASCO Annual Meeting and discusses the evolving treatment landscape.

A panel of experts summarizes the current treatment landscape for early and metastatic HER2+ breast cancer and discusses recent data updates in these settings, including those presented at the 2023 American Society of Clinical Oncology (ASCO) meeting.

Moderator Zofia Piotrowska, MD, MHS introduces an upcoming Onclive Peer Exchange discussion with expert panelists concerning recent updates from in the diagnosis and treatment of EGFR Mutant NSCLC.

Experts review recent updates in the treatment of HCC and discuss how evidence from clinical trials and real-world settings can be applied to clinical practice to improve patient outcomes.

Following the 2023 ASCO Annual Meeting, experts on HR+/HER2- breast cancer discuss the evolving treatment landscape and data updates on frontline and later-line therapies.

Expert oncologists review recent updates in the treatment landscape of prostate cancer and consider how data will impact their own practice.

Expert panelists review data presented at ASCO 2023 and surrounding meetings to elucidate the current treatment landscape of renal cell carcinoma.

Centering discussion on several patient scenarios, expert panelists review recent clinical data and consider how it has impacted their management of patients with small cell lung cancer (SCLC).

An expert perspective pertaining to treatment advances in early-stage non-small cell lung cancer and how to best apply data from ASCO 2023 into daily practice.

Moderator Michael Bishop, MD leads a discussion with panelists Hannah Choe, MD, Doris M. Ponce, MD, and Bart L Scott, MD, concerning recent updates in the prevention, diagnosis, and treatment of Graft-Versus-Host Disease.

Moderator Naval G. Daver, MD leads a discussion with panelists Amir Fathi, MD, Margaret T. Kasner, MD, Eunice S. Wang, MD, providing an overview of AML pathogenesis and molecular subtypes, standard-of-care treatment approaches, and emergent therapies.

A panel of experts review several updates in myelodysplastic syndromes (MDS) that were presented at ASCO 2023 and other recent meetings and discuss how the data may change treatment approaches in clinical practice.

Expert panelists reflect on the current state of molecular testing and management in patients with metastatic colorectal cancer, reviewing recent clinical data and considering changes in real-world practice.

Key opinion leaders review recent clinical data in the field of multiple myeloma management and consider how the treatment paradigm has evolved.